Population
194 potent uncharged hERG active chemical compounds
Design
Preclinical
Authors
Loading...
May inform hERG-sparing design in neutral compounds; leaves open prospective validation before clinical use.
The study proposes a novel pharmacophore model to predict and eliminate hERG channel blockade liability in uncharged chemical series.
Alex M. Aronov (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: